2016-04-06 15:29
Yiling pharmaceutical three annual export volume contrarian growth of 12 times
[in the face of straight news network Beijing April 6 news] (Securities Times of China's foreign trade continued to slump, foreign trade medicines and slow growth of the situation of poor, Yiling International Pharmaceutical by virtue of the intensive cultivation of the elite team, excellent quality and international market, the implementation of "transfer processing - International Registration - Patent Drugs" three-step strategy, contrarian, three years export growth 12 times, especially in 2015, the chemical medicine exports doubled.
Yiling pharmaceutical is mainly to the innovation of Chinese medicine production enterprises, collaterals disease theory innovation to lead the research and development of new drugs, the implementation of the transformation of scientific and technological achievements, the Yiling pharmaceutical has become a model for the transformation of traditional Chinese medicine innovation achievements and reach billions of sales only in the field of modern Chinese medicine, has to bear the major projects in the national 973 Plan, 863, the national "Eleventh Five Year" support, countries "1025" creation of major new drugs and other countries more than 30 items, and won five national awards, more than 10 R & D patent drugs, access to domestic and foreign patents 350 items.
Yiling pharmaceutical to conform with international, and actively carry out internationalization strategy of chemical preparation, from 2009 to start the layout of the pharmaceutical industry, established a branch of the internationalization of R & D, quality, production, marketing team, senior managers are in Europe and the United States market has many years of business history, has long-term multinational pharmaceutical company working background and professional experience, in Europe and the United States the generics market, strong market analysis ability, the ability of R & D, production management, product planning and marketing capabilities.
Yiling Pharmaceutical International Pharmaceutical in Beijing, Shijiazhuang, establish the common oral solid preparation, non cytotoxic oral solid preparation and sex hormone oral solid formulation R & D and production base, hormones, anti tumor drugs, controlled release agent development platform has been established to master a number of sustained or controlled release technology, completed dozens of technology transfer projects and patent medicine, non international registration of patent medicine. Workshop production by the international biological engineering design company in accordance with the standards of the EU GMP (for quality control of pharmaceutical production specification) and the U. S. Food and Drug Administration (FDA) for conceptual design and the layout of the workshop, production workshop repeatedly through the GMP certification in the United States, Britain, Canada, Australia, New Zealand, products have been exported to the United Kingdom, Canada, New Zealand, Germany and many countries and regions.
Yiling pharmaceutical treatment of tumor molecular target to drugs, the treatment of stroke, Parkinson's disease and pain, a kind of new drug research and development has made breakthrough progress. International Pharmaceutical three business modules, OEM, clinical sample processing, independent research and development of ANDA (abbreviated new drug application), after a solid work and market development, have been developed by leaps and bounds. Oral solid preparation into Europe and the United States to regulate the market, especially in the pics member states in the field of international pharmaceutical won the affirmation and the five products in New Zealand possession rate of 80%, two products in the UK market share of more than 60%, 2 products in Canada and Germany reached more than 40%, the product all over Europe and the United States terminal network become one of the largest of China's preparation export enterprises. Yiling pharmaceutical "fortune" global top 500 enterprises in the production of a large number of clinical samples, and obtained the quality. By the Yiling pharmaceutical Wanzhou International Pharmaceutical leading to the U. S. Food and Drug Administration (FDA) declared a number of Anda (abbreviated new drug application) products, to the United States as a starting point to Europe, expanding the market will be very broad, February 1, 2016, Yiling pharmaceutical flutter paracetamol became Chinese first to its own brand in the United States, local direct sales to the terminal products. Yiling pharmaceutical established a subsidiary in the United States, Britain and other countries, the international market will be more broad and deep. Among them, the United States subsidiary has completed the registration of the United States 27 states wholesale license, is expected to be completed in the first half of 2016, the remaining 23 states of the wholesale license registration, to achieve sales network covering the United states.
In December 2015, patent medicine even the flower Qingwen capsule won has been approved to enter the United States FDA phase II clinical study; traditional Chinese medicine Tongxinluo capsule, ginseng pine Yangxin capsule, Qili Qiangxin Capsule a number of innovative Chinese medicine has entered Korea, Vietnam, Malaysia, Singapore, Indonesia, and Canada, Russia etc. Market. Yiling pharmaceutical preparation was named China international pharmaceutical enterprises pilot enterprises.
In February 14, 2016, Premier Li Keqiang chaired a State Council executive meeting to support the development of domestic and international registration certificate of patent for the original research and brand. Yiling Pharmaceutical International Pharmaceutical intends to invest 1 billion 100 million yuan, construction of 80 thousand square meters, capacity of 20 billion pieces per grain of international pharmaceutical workshop. Through research and development, the production of independent products and OEM production, to the United States, the European Union and other overseas market sales of cardio cerebral vascular diseases, nervous system, blood system, anti rheumatism class chemical generics. Yiling International Pharmaceutical Chemicals international industrial project construction, will further enhance the own preparations international development ability, in order to protect the enterprise products to be able smoothly develop developed countries such as Europe and America market. 3
(original title: the layout of the international pharmaceutical industry Yiling pharmaceutical three annual export volume contrarian growth of 12 times)
Editor: Xiao Shen
Interpretation of the news hot spots, showing sensitive events, more exclusive analysis, in the "things" WeChat, scan two-dimensional code free reading.
|